Michael T Amato, MBA - President & Chief Executive Officer

Michael Amato currently serves as the President and CEO of InspiRx Inc. Born in Brooklyn, New York, Michael earned his MBA from Bedford University in London, UK. He has over 40 years experience in the medical device industry including several key senior management positions at DHD Medical, Trudell Medical International, and Monaghan Medical Corporation. Michael was most recently Senior Vice President of Special Accounts and Professional relations at TMI/MMC. Prior to this he was Vice President of Sales and Marketing at MMC where he helped position them as the worldwide leader with their Valved-holding chambers used with pressurize Meter Dose Inhalers.

Michael also serves on several boards including nonprofit American Respiratory Care Foundation and The Allergy Asthma Network Mothers of Asthmatics. Michael has also served on the US Food and Drug Administration Device Advisory Panel. 

Dr. Ronnie Toddywala, Ph.D., MBA - Chief Technology Officer

Ronnie Toddywala currently serves as the Chief Technology Officer of Nostrum Technologies, LLC. Born in Mumbai, India, Ronnie holds a Ph.D. in Pharmaceutical Sciences and an MBA from Rutgers University. He has 20+ years' experience in the pharmaceutical, consumer and medical device industry including several key scientific and management positions at Colgate Palmolive Company and Johnson & Johnson. Prior to joining Nostrum, Ronnie was the Vice President and Venture Leader for the SNS Johnson & Johnson Internal Venture, a Johnson & Johnson company. Here, he led a small J&J venture with a focus on neurostimulation technologies. Prior to being a venture leader, he served as a Board Member and Vice President of Gynecare, a small medical device division within ETHICON, a Johnson & Johnson Company. Gynecare focused on medical devices for Women’s Health in the area of incontinence, uterine disorders, contraception and cancer. He has spent over ten years in different areas of Research & Development including medical devices such as electromechanical devices, tissue reinforcement and biomaterials as well as pharmaceuticals such as liquids, semisolids, tablets and transdermal delivery systems. In addition to R&D, he also has experience in Business Development and Marketing of Consumer products. In his short career he has led launches of over 25 key products into the marketplace. He has also authored several patents, publications and book chapters.

Michael T Newhouse, MD, MSc, FRCP(C), FACP, FCCP, Clinical Professor of Medicine, Faculty of Health Sciences - McMaster University, Hamilton, ON Canada - Chief Medical Officer

Michael Newhouse obtained his MD from Queen’s University, Kingston, ON, in 1959 after an exchange scholarship year in Munich, Germany. He graduated MSc in Experimental Medicine from McGill University/Royal Victoria Hospital and simultaneously completed his postgraduate studies in pulmonology/Cardiology in 1964.

The same year he established a pulmonary function lab and clinical pulmonology service at St Joseph’s Hospital, Hamilton, Ontario and in 1965 founded what eventually became the McMaster Medical Aerosol Research Laboratory (with the assistance of Myrna Dolovich, P.Eng) where he and colleagues first introduced the use of the gamma camera and aerosol scintigraphy to study mucus clearance in Cystic Fibrosis [CF] (with Dr. J. Sanchis), to evaluate the effect of air pollutants on normal volunteers (with Dr. R. Woolf) and to determine lung aerosol drug dose and distribution (with Dr. R. Ruffin). With Carol Rossman, he studied mucus clearance on the effect of a number of physical and physiological variables in CF. She was the first to observe that cilia in the so-called “Immotile Cilia Syndrome” actually moved slowly and with inefficient and abnormal wave motion. These congenital disorders of the ciliary axoneme were subsequently renamed “Primary Ciliary Dyskinesia” to reflect this observation.

Perhaps the most important contribution of the aerosol lab to clinical pulmonary medicine was the development, in the early 1980s, with several colleagues (Dr. D. Corr, M. Dolovich P Eng, Dr. R. Ruffin, Mr. D. McCormick and others) of the AeroChamber, a small, valved, aerosol holding chamber that greatly improved the reliability of aerosol delivery from MDIs. It helped to solve the widespread, hand-breath co-ordination problem in adults and made it possible to virtually eliminate the need for expensive and slow wet nebulization for administering aerosol medications by tidal breathing (chiefly bronchodilators and corticosteroids) to infants, children, and the aged and/or infirm and eventually, even to horses (after studies in collaboration with the equine division-DrsViel and Tesarowski) at the U of Guelph, ON.

With Dr Jeff Norman of the Dept of Epidemiology of the McMaster Health Sciences Faculty he became involved, for almost a decade, in revealing, for the nonsense it was, the pseudo-science surrounding the hypothesized adverse health effects of urea-formaldehyde foam insulation and of formaldehyde in plywood and broadloom carpeting.

He has published about 150 peer-reviewed articles, has been co-editor of professional and lay books, has been a member of the editorial board of several journals, and has been author or co-author of numerous book chapters.

Ronald J. Shebuski, Ph.D. - Vice President, Pharmaceutical Research & Development

Dr. Shebuski has over 25 years of experience in the pharmaceutical industry and served as the Director of Cardiovascular Therapeutics at Pharmacia & Upjohn in Kalamazoo, MI from 1990-1998. He established a Cardiovascular Research Consulting Firm in 1998 and served small, mid and large pharma in many aspects of drug discovery and development until assuming his current position in 2016 as Vice-President of Pharmaceutical R&D of InspiRx, Inc. in Durham, NC.

Previous to directing the cardiovascular group at Pharmacia & Upjohn, where he managed the team responsible for FDA approval of the Class III anti-arrhythmic agent, Corvert®, Ron was a Senior Scientist responsible for leading cardiovascular drug discovery teams at Merck Research Laboratories and Smith Kline & French in the Philadelphia area. His primary field of research has focused on thrombosis and the development of effective new thrombolytic, anti-platelet and anti-coagulant therapies. At Merck, Ron led the in vivo discovery and development effort which culminated in the identification and eventual FDA approval of the anti-platelet GPIIb/IIIa antagonist, Aggrastat®. He also led development teams in identification of novel factor Xa and P- selectin antagonists at Merck and Pharmacia & Upjohn, respectively.

Dr. Shebuski received his B.S. Degree in Microbiology from the University of Wisconsin at Madison (1976) and Ph.D. Degree in Pharmacology from the University of Minnesota Medical School (1985). Further, Dr. Shebuski is expert in FDA regulations and has an ongoing appointment (since 2009) with FDA as a Special Government Employee (SGE) in the CardioRenal Division of CDER (Center for Drug Evaluation and Research).

Michael T Amato III - Director of Sales & Marketing

Michael T. Amato III currently serves as Director of Sales and Marketing of InspiRx Inc. Born in Syracuse, New York, Michael earned his Bachelor of Science, with a Major in Business Administration & Marketing and a Minor in Spanish Language, at the University North Carolina at Wilmington. His experience in the medical and pharmaceutical industry began as a Pharmaceutical Representative, building a foundation of knowledge related to patients, physicians and the healthcare system, enabling a comprehensive understanding of the market to better serve.

Michael is happily married with a daughter and a son and resides in North Carolina.